Intratumor heterogeneity is the main obstacle to effective cancer treatment and personalized
medicine. Both genetic and epigenetic sources of intratumor heterogeneity are well …

The field of cancer diagnostics has recently been impacted by new and exciting
developments in the area of liquid biopsy. A liquid biopsy is a minimally invasive alternative …

Several hundred clinical trials currently explore the role of circulating tumor cell (CTC)
analysis for therapy decisions, but assays are lacking for comprehensive molecular …

Circulating tumor cells (CTCs) are very attractive surrogate markers for systemic cancer.
Currently, major efforts are being made to use these rare cells in the sense of a liquid biopsy …

Mouse models indicate that metastatic dissemination occurs extremely early; however, the
timing in human cancers is unknown. We therefore determined the time point of metastatic …

Background Therapeutic decisions in cancer are generally guided by molecular biomarkers
or, for some newer therapeutics, primary tumor genotype. However, because biomarkers or …

Simple Summary With estimated numbers of 1–10 per mL of blood, circulating tumor cells
(CTCs) are extremely rare compared to white (a few million) or red (billions) blood cells …

Single-cell DNA sequencing technologies are enabling the study of mutations and their
evolutionary trajectories in cancer. Somatic copy number aberrations (CNAs) have been …

Background Single-cell micro-metastases of solid tumors often occur in the bone marrow.
These disseminated tumor cells (DTCs) may resist therapy and lay dormant or progress to …

Purpose The presence of disseminated tumor cells (DTCs) in bone marrow (BM) predicts
survival in early breast cancer. This study explores the use of DTCs for identification of …